nasdaq:enta
|
40481
|
Apr 14th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 13th, 2024 10:59PM
|
Apr 14th, 2024 10:57AM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 13th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 12th, 2024 10:50PM
|
Apr 13th, 2024 11:25AM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 12th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 11th, 2024 10:54PM
|
Apr 12th, 2024 08:20AM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 11th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 10th, 2024 11:27PM
|
Apr 11th, 2024 11:04AM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 10th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 9th, 2024 10:57PM
|
Apr 10th, 2024 05:12PM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 9th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 8th, 2024 11:08PM
|
Apr 9th, 2024 09:54AM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 8th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 7th, 2024 11:34PM
|
Apr 8th, 2024 06:52PM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 7th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 6th, 2024 11:04PM
|
Apr 6th, 2024 11:04PM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 6th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
164.00
|
Open
|
|
Apr 5th, 2024 11:05PM
|
Apr 5th, 2024 11:05PM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:enta
|
40481
|
Apr 5th, 2024 12:00AM
|
Enanta Pharmaceuticals
|
9.3K
|
163.00
|
Open
|
|
Apr 4th, 2024 11:32PM
|
Apr 4th, 2024 11:32PM
|
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs in virology and immunology. Enanta’s research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
|
Open
|
Virology and Immunology
|
Open
|
500 Arsenal Street
|
Watertown
|
MA
|
US
|
02472
|
|
Enanta Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|